Mumbai, June 12 : The deal in which Ranbaxy Laboratories Ltd India’s largest pharmaceutical company was sold off to a Japanese-based Daiichi Sankyo Co. has been appreciated by experts.
ChrysCapital Managing Director Sanjiv Kaul, an ex-Ranbaxy executive and a sector analyst said, “Commercially, it is an awesome deal. However, Ranbaxy was the all-conquering Indian hero and should have been the last man standing instead of being the first to capitulate. A huge positive for Ranbaxy but a negative for Indian pharma.”